Sinopharm Group CoSHTDF -2.67%78 Days Payable is 103.76 as of Dec. 2025, which is 5% above its 10-year median of 98.85. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $3.03 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 117 Medical Distribution companies, Sinopharm Group Co ranks better than 67.52% on this metric.
The historical rank and industry rank for Sinopharm Group Co's Days Payable or its related term are showing as below:
SHTDF'
s Days Payable Range Over the Past 10 Years
Min: 90.95 Med: 98.85 Max: 106.54
Current: 104.87
During the past 13 years, Sinopharm Group Co's highest Days Payable was 106.54. The lowest was 90.95. And the median was 98.85.
SHTDF's Days Payable is ranked better than 67.52% of 117
companies
in the Medical Distribution industry
Industry Median: 79.11
vs SHTDF: 104.87
Sinopharm Group Co's Days Payable
declined
from Dec. 2024 (106.87) to Dec. 2025 (103.76).
It may suggest that Sinopharm Group Coaccelerated paying its suppliers.
Sinopharm Group Co Days Payable Related Terms
Sinopharm Group Co Days Payable Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sinopharm Group Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sinopharm Group Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co (SHTDF) has a Days Payable of 103.76 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sinopharm Group Co and its competitors. This is near median its historical median of 98.85. Over the past decade, Sinopharm Group Co's Days Payable has ranged from 90.95 to 106.54. According to the industry distribution chart, Sinopharm Group Co ranks #38 out of 117 companies in the Medical Distribution industry, placing it in the top 32.5%.
Is Sinopharm Group Co's Days Payable too high?
Sinopharm Group Co's current Days Payable of 103.76 is near median its 10-year median of 98.85. Over the past 10 years, this metric has ranged from a low of 90.95 to a high of 106.54. The Medical Distribution industry median Days Payable is 79.11. Sinopharm Group Co's value of 103.76 is 31.2% above this industry median. Based on the distribution chart, Sinopharm Group Co ranks #38 out of 117 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Days Payable compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #38 out of 117 companies for Days Payable. This puts Sinopharm Group Co in the upper half of its industry. The industry median Days Payable is 79.11. Sinopharm Group Co's value of 103.76 is 31.2% above this benchmark. Historically, Sinopharm Group Co's own Days Payable has ranged from 90.95 to 106.54 over the past decade. While the company's 10-year median is 98.85 vs. the industry median of 79.11, Sinopharm Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 79.11, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Days Payable of 103.76 is 31.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median Days Payable is 79.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Days Payable is 103.76, which is near median its own 10-year median of 98.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.03, compared to a current price of $2.29 — trading 24.5% below its estimated fair value. The current Days Payable is 103.76, which is near median its 10-year median of 98.85 and 31.2% above the Medical Distribution industry median of 79.11. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Days Payable is 103.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.29 is trading 24.5% below its estimated GF Value™ of $3.03.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
Days Payable: 103.76 (near median its 10-year median of 98.85)
GF Value™: $3.03 vs. price of $2.29 (24.5% below fair value)
Industry Position: 31.2% above the Medical Distribution median (#38 of 117)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
